Theriva Biologics, Inc. Logo

Theriva Biologics, Inc.

Develops systemic oncolytic virus therapies to selectively destroy difficult-to-treat cancers.

TOVX | US

Overview

Corporate Details

ISIN(s):
US87164U5083 (+1 more)
LEI:
Country:
United States of America
Address:
9605 MEDICAL CENTER DRIVE, 20850 ROCKVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Theriva Biologics, Inc. is a clinical-stage immuno-oncology company developing a new class of oncolytic virus therapeutics. The company's platform engineers viruses for systemic delivery, designed to overcome the protective barriers of solid tumors and selectively destroy cancer cells. These developmental therapies are intended to treat a broad range of difficult-to-treat cancers and have the potential to be combined with or enhance current standard-of-care treatments. Theriva's lead candidates are being evaluated in clinical trials to address diseases in areas of high unmet medical need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Theriva Biologics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Theriva Biologics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Theriva Biologics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.